Chartwell Investment Partners LLC Purchases Shares of 83,138 Horizon Pharma PLC (HZNP)
Chartwell Investment Partners LLC purchased a new position in shares of Horizon Pharma PLC (NASDAQ:HZNP) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 83,138 shares of the biopharmaceutical company’s stock, valued at approximately $2,197,000.
Other large investors also recently made changes to their positions in the company. Rothschild & Co. Asset Management US Inc. increased its holdings in Horizon Pharma by 0.6% in the fourth quarter. Rothschild & Co. Asset Management US Inc. now owns 1,662,350 shares of the biopharmaceutical company’s stock valued at $32,482,000 after purchasing an additional 10,573 shares during the period. Rhenman & Partners Asset Management AB increased its holdings in Horizon Pharma by 3.2% in the fourth quarter. Rhenman & Partners Asset Management AB now owns 946,060 shares of the biopharmaceutical company’s stock valued at $18,486,000 after purchasing an additional 29,009 shares during the period. Mizuho Securities USA LLC increased its holdings in Horizon Pharma by 124.1% in the fourth quarter. Mizuho Securities USA LLC now owns 60,500 shares of the biopharmaceutical company’s stock valued at $1,182,000 after purchasing an additional 33,500 shares during the period. Sheets Smith Wealth Management acquired a new stake in Horizon Pharma in the fourth quarter valued at $314,000. Finally, Canada Pension Plan Investment Board increased its holdings in Horizon Pharma by 15.4% in the fourth quarter. Canada Pension Plan Investment Board now owns 564,500 shares of the biopharmaceutical company’s stock valued at $11,029,000 after purchasing an additional 75,500 shares during the period. Institutional investors own 82.01% of the company’s stock.
HZNP has been the subject of a number of recent research reports. BidaskClub downgraded Horizon Pharma from a “strong-buy” rating to a “buy” rating in a report on Wednesday, February 20th. Zacks Investment Research upgraded Horizon Pharma from a “sell” rating to a “hold” rating in a report on Friday, January 25th. Jefferies Financial Group increased their price objective on Horizon Pharma to $34.00 and gave the company a “buy” rating in a report on Friday, March 1st. Cowen set a $33.00 price objective on Horizon Pharma and gave the company a “buy” rating in a report on Thursday, February 28th. Finally, Morgan Stanley upgraded Horizon Pharma from an “equal weight” rating to an “overweight” rating and set a $32.00 price objective for the company in a report on Friday, March 8th. Five research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Horizon Pharma currently has a consensus rating of “Buy” and an average price target of $30.73.
Horizon Pharma (NASDAQ:HZNP) last issued its quarterly earnings results on Wednesday, February 27th. The biopharmaceutical company reported $0.67 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.54 by $0.13. Horizon Pharma had a positive return on equity of 34.09% and a negative net margin of 6.34%. The firm had revenue of $355.50 million during the quarter, compared to the consensus estimate of $334.22 million. During the same period last year, the business posted $0.29 EPS. The business’s revenue was up 29.6% compared to the same quarter last year. On average, sell-side analysts forecast that Horizon Pharma PLC will post 1.7 earnings per share for the current year.
In other news, EVP Geoffrey M. Curtis sold 10,080 shares of the stock in a transaction dated Monday, February 25th. The shares were sold at an average price of $21.21, for a total transaction of $213,796.80. Following the transaction, the executive vice president now owns 35,367 shares of the company’s stock, valued at approximately $750,134.07. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Geoffrey M. Curtis sold 8,835 shares of the stock in a transaction dated Tuesday, February 5th. The stock was sold at an average price of $23.15, for a total transaction of $204,530.25. Following the transaction, the executive vice president now directly owns 32,202 shares in the company, valued at approximately $745,476.30. The disclosure for this sale can be found here. 3.90% of the stock is owned by corporate insiders.
Horizon Pharma Profile
Horizon Pharma Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. The company's orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.
Further Reading: Special Dividends
Want to see what other hedge funds are holding HZNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Horizon Pharma PLC (NASDAQ:HZNP).
Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.